[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.163.147.69. Please contact the publisher to request reinstatement.
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
[Skip to Content Landing]
Observation
May 1998

Reversible Segmental Cerebral Arterial Vasospasm and Cerebral InfarctionPossible Association With Excessive Use of Sumatriptan and Midrin

Author Affiliations

From the Department of Neurology, Mayo Clinic Jacksonville, Jacksonville, Fla (Dr Meschia); and the Indiana University School of Medicine, Indianapolis (Drs Malkoff and Biller).

Arch Neurol. 1998;55(5):712-714. doi:10.1001/archneur.55.5.712
Abstract

Objective  To describe a patient who developed reversible segmental cerebral arterial vasospasm and cerebral infarction while taking excessive amounts of sumatriptan succinate and a combination drug (Midrin) consisting of isometheptene mucate, 65 mg, dichloralphenazone, 100 mg, and acetaminophen, 325 mg.

Design  Case report.

Setting  Tertiary care center.

Patient  A 43-year-old man who developed a left occipital infarct after taking a total of 23 sumatriptan succinate tablets (25 mg per tablet) and 32 Midrin tablets during a 7-day period and who on digital subtraction angiography was shown to have segmental cerebral arterial narrowing in multiple vessels. An extensive evaluation for other possible risk factors for cerebral infarction was unrevealing.

Main Outcome and Results  Discontinuation of sumatriptan and Midrin regimens and administration of nicardipine hydrochloride led to nearly total resolution of the angiographic findings, and the patient had no recurrent strokes.

Conclusions  One should consider the diagnosis of drug-induced vasospasm in patients with cerebral infarction and a history of excessive use of sumatriptan and Midrin. The initial angiographic abnormalities may resemble those found in patients with primary angiitis of the central nervous system.

WE DESCRIBE a patient who experienced a posterior cerebral artery territory infarction while taking an excess of sumatriptan succinate and a combination drug (Midrin) consisting of isometheptene mucate, dichloralphenazone, and acetaminophen and who was found on serial digital subtraction angiography to have reversible segmental arterial vasospasm. Four patients with cerebral infarction in association with sumatriptan use have been described previously (Table 1).13 However, 1 of these patients had an underlying sagittal sinus thrombosis. In none of these cases was cerebral angiography reported. The importance of differentiating this condition from granulomatous angiitis of the central nervous system is discussed.

Patients With Ischemic Stroke Associated With Sumatriptan Use*
Patients With Ischemic Stroke Associated With Sumatriptan Use*
REPORT OF A CASE

A 43-year-old male mathematics teacher was healthy until he suddenly felt a pulsatile, bioccipital headache while lifting an inner tube (day 0). The headache lasted several hours and was associated with nausea but not vomiting. He began having headaches every other day, lasting 2 to 24 hours. None of the recurrent headaches were as severe as the initial headache, and none were associated with nausea, aura, photophobia, or phonophobia. He sought medical attention when over-the-counter medications failed to relieve the headaches. Results of a computed tomographic scan of the head obtained on day 3 were normal. At that time he was treated with prednisone and intramuscular meperidine hydrochloride. The prednisone was tapered during the next 6 days. The patient was prescribed Midrin on day 7, and getting little relief from it, oral sumatriptan was added on day 11. The patient noted a fixed right homonymous visual defect on day 12. Before stopping his medication use on day 14, he took a total of 32 Midrin tablets and 23 sumatriptan succinate (25-mg) tablets. A lumbar puncture showed clear, colorless fluid with a protein level of 52 mg/dL, a glucose level of 3.4 mmol/L(61 mg/dL), no red or white blood cells, and nonreactive results from cerebrospinal fluid VDRL. Computed tomography and magnetic resonance imaging of the head performed on day 17 showed a 2.5×2.5-cm, left occipitoparietal infarct without hemorrhage or mass effect (Figure 1, D). The patient was transferred to our care. A 3-vessel digital subtraction angiogram on day 20 (8 days following the fixed visual field defect) showed segmental narrowing of small- to medium-sized arteries in the anterior and posterior circulation bilaterally (Figure 1, A-C). A repeated cerebrospinal fluid analysis the same day showed protein levels of 95 mg/dL; a glucose level of 3.8 mmol/L (68 mg/dL); red blood cells, 39×106/L, and white blood cells, 12×106/L. Cerebrospinal fluid cultures were negative for organisms.

Figure 1.
Bilateral carotid (A and B), posterior circulation (C), and digital subtraction angiograms initially showing segmental arterial narrowing (arrows), and noncontrasted computed tomographic head scan demonstrating ischemic stroke in the left posterior cerebral artery territory (D).

Bilateral carotid (A and B), posterior circulation (C), and digital subtraction angiograms initially showing segmental arterial narrowing (arrows), and noncontrasted computed tomographic head scan demonstrating ischemic stroke in the left posterior cerebral artery territory (D).

Results of transesophageal echocardiography and electrocardiography were normal. Results of a complete blood cell count, routine blood chemistry tests, chest x-ray, and urinalysis were normal. The results of the following additional tests showed no abnormalities: serum rapid plasma reagin, antinuclear antibody, rheumatoid factor, antiphospholipid antibody screen, and antithrombin III. Factor V Leiden mutation was not detected by DNA polymerase chain reaction. The patient was treated with oral nicardipine hydrochloride and aspirin (325 mg/d). An angiogram repeated on day 59 showed nearly complete resolution of the abnormalities previously seen (Figure 2). The patient remains free of headaches and has had nearly complete resolution of his hemianopia.

Figure 2.
Normalization of bilateral carotid angiogram taken 39 days after the one shown in parts A and B in Figure 1.

Normalization of bilateral carotid angiogram taken 39 days after the one shown in parts A and B in Figure 1.

COMMENT

Sumatriptan, administered either intravenously or orally, has been associated with angina pectoris, myocardial infarction, and ventricular arrhythmias in patients both with and without underlying coronary atherosclerosis.47 Our patient had angiographic evidence of reversible segmental cerebral arterial vasospasm analogous to the vasospasm seen on coronary angiography. There are pharmacological reasons to think sumatriptan caused vasospasm in our patient. Sumatriptan is an agonist with affinity for 5-HT1B (serotonin), 5-HT1D, and contractile 5-HT1–like receptors. It induces vasospasm in isolated nonhuman8,9 and human10 basilar artery preparations. In a recent review, Parsons11 concluded that there are contractile serotonin receptors in large pre– and post–circle of Willis vessels and relaxation receptors in small resistance pial arterioles.

We cannot entirely exclude the possibility that our patient had idiopathic reversible cerebral arterial vasospasm like the patients described by Call and colleagues,12 and that the use of sumatriptan and Midrin was incidental. However, the angiographic features of our patient differed from those described by Call et al, whose patients had vasospasm predominantly involving arteries around the circle of Willis. The luminal irregularities seen in our patient were more diffusely distributed. Midrin use was a possible contributing cause of vasospasm in our patient. Midrin contains isometheptene mucate (65 mg per tablet), a sympathomimetic agent implicated as the cause of segmental vasospasm in a postpartum woman who ingested 10 tablets of Midrin in 1 week.13

Our patient had angiographic findings similar to those seen in primary angiitis of the central nervous system. A meningocortical biopsy was not done because we had an alternative explanation for our patient's angiographic abnormalities and because he had no clinical or serologic evidence of systemic vasculitis. In one study of 30 consecutively referred patients, conventional cerebral angiography had less than 30% specificity for primary angiitis of the central nervous system.14 The magnetic resonance imaging scan of our patient's head showed only the single infarction. Multiple infarcts are commonly seen on magnetic resonance imaging scans in patients with primary angiitis of the central nervous system.15

The combined use of sumatriptan and Midrin should be considered among the nearly 30 conditions that can resemble primary angiitis of the central nervous system.16 One should consider the diagnosis of drug-induced vasospasm in patients with cerebral infarction and a history of excessive sumatriptan and/or Midrin use. It might be appropriate to consider the establishment of a registry to determine the incidence of ischemic stroke in users of sumatriptan and to investigate whether the coadministration of Midrin predisposes to ischemic stroke. Nicardipine is efficacious in vasospasm induced by subarachnoid hemorrhage.17 Nicardipine may also be useful in patients like ours who have drug-induced cerebral vasospasm.

Back to top
Article Information

Accepted for publication August 25, 1997.

Reprints: James F. Meschia, MD, Department of Neurology, Mayo Clinic Jacksonville, 4500 San Pablo Rd, Jacksonville, FL 32224.

References
1.
Luman  WGray  RS Adverse reactions associated with sumatriptan. Lancet. 1993;3411091- 1092Article
2.
Cavazos  JECaress  JBChilukuri  VR Sumatriptan-induced stroke in sagittal sinus thrombosis. Lancet. 1994;3431105- 1106Article
3.
Jayamaha  JELStreet  MK Fatal cerebellar infarction in a migraine sufferer whilst receiving sumatriptan. Intensive Care Med. 1995;2182- 83Article
4.
Mueller  LGallagher  RMCiervo  CA Vasospasm-induced myocardial infarction with sumatriptan. Headache. 1996;36329- 331Article
5.
Ottervanger  JPStricker  BHC Cardiovascular adverse reactions to sumatriptan: cause for concern? CNS Drugs. 1996;390- 98Article
6.
O'Connor  PGladstone  P Oral sumatriptan-associated transmural myocardial infarction. Neurology. 1995;452274- 2276Article
7.
Kelly  KM Cardiac arrest following use of sumatriptan. Neurology. 1995;451211- 1213Article
8.
Connor  HEFeniuk  WHumphrey  PPA Characterization of 5-HT receptors mediating contraction of canine and primate basilar artery by use of GR43175, a selective 5-HT1-like receptor agonist. Br J Pharmacol. 1989;96379- 387Article
9.
Parsons  AAWhalley  ET Evidence for the presence of 5-HT1-like receptors in rabbit isolated basilar arteries. Eur J Pharmacol. 1989;174189- 196Article
10.
Parsons  AAWhalley  ETFeniuk  WConnor  HEHumphrey  PPA 5-HT1-like receptors mediate 5-hydroxytryptamine-induced contraction of human basilar artery. Br J Pharmacol. 1989;96434- 449Article
11.
Parsons  AA 5-HT receptors in human and animal cerebrovasculature. Trends Pharmacol Sci. 1991;12310- 315Article
12.
Call  GKFleming  MCSealfon  SLevine  HKistler  JPFisher  CM Reversible cerebral segmental vasoconstriction. Stroke. 1988;191159- 1170Article
13.
Raroque  HG  JrTesfa  GPurdy  P Postpartum cerebral angiopathy: is there a role for sympathomimetic drugs? Stroke. 1993;242108- 2110Article
14.
Grennan  TOGrossman  RIGoldberg  HI Cerebral vasculitis: MR imaging and angiographic correlation. Radiology. 1992;18265- 72Article
15.
Duna  GFCalabrese  LH Limitations of invasive modalities in the diagnosis of primary angiitis of the central nervous system. J Rheumatol. 1995;22662- 667
16.
Calabrese  LHFurlan  AGGragg  LARopos  TJ Primary angiitis of the central nervous system: diagnostic criteria and clinical approach. Cleve Clin J Med. 1992;59293- 306Article
17.
Haley  ECKassell  NFTorner  JC  et al.  A randomized controlled trial of high-dose intravenous nicardipine in aneurysmal subarachnoid hemorrhage. J Neurosurg. 1993;78537- 547Article
×